ARCHIVES

Experts Say Interpretable Results Unlikely In Burzynski’s Antineoplastons Studies

This article is from The Cancer Letter archive.

Vol. 24 No. 36 | September 25, 1998

Download PDF Visit The Full Archive

Related Articles

Pathology Review Confirms Reserpine As Carcinogen

March 14, 1980

NCI Director asks NCAB to pray for him.

June 18, 2004

DCPC Advisors Consider Asking DRG For Section On Prevention & Control

May 14, 1993

CCOP Recompetition Approved, “Institutionalized;” Board Okays Concept For Eight Minority CCOPs

February 3, 1989

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

The Clinical Trials Working Group: NCI panel considers plan to centralize clinical trial review and prioritization. NCI director faults system for duplication, “equivocal results.”

August 13, 2004